Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Chapter and Conference Paper
Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells
A substantial number of Phase I and Phase II clinical trials of interleukin-2 (IL-2) alone or combined with adoptive transfer of lymphokine-activated killer (LAK) cells in the treatment of cancer patients had ...